Overview

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Status:
NOT_YET_RECRUITING

Trial end date:
2031-05-15

Target enrollment:

Participant gender:

Summary

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Phase:

PHASE2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Carboplatin
Cisplatin
Pemetrexed